AI in Oncology NKI has a clear emphasis on AI-driven cancer research and recently unveiled ARTIMES, an AI model to measure tumor volumes for treatment response in pleural mesothelioma. This indicates a strong potential to partner on AI analytics, imaging, and decision-support tools for oncology.

Clinical Collaboration Active partnerships with patient groups and international collaborators (e.g., LORD trial with Borstkanker and Europa Donna) suggest openness to joint research initiatives, patient-centric studies, and opportunities to offer trial management, data collaboration platforms, and patient recruitment services.

AI imaging momentum BrainMets AI collaboration to detect brain metastases demonstrates a track record in advanced imaging analytics. This presents upsell potential for imaging workflow automation, AI model deployment, and cloud-based analytics for radiology teams.

Thought leadership High-profile events and recognition (SITC keynote by Ton Schumacher, Spinoza Prize for the director) position NKI as a leading research partner. This can be leveraged to propose strategic research partnerships, grant-backed projects, and co-development initiatives.

Tech stack readiness NKI employs modern cloud and data tooling (AWS, Google Cloud, Databricks, Kubernetes, SAS) indicating readiness for data platforms, scalable analytics, and enterprise-grade collaborations. Opportunities exist to offer integration services, managed cloud partnerships, and data stewardship offerings.